TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05020665
Drug: Anthracycline
Normalized name: Anthracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either daunorubicin or idarubicin was administered via slow intravenous (IV) push
Study: NCT05342623
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken orally 1 time/day
Study: NCT06363370
Drug: Inhalation Solution Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Inhalation Solution Placebo
Study: NCT04797780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05769075
Drug: TY-2136b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: TY-2136b PO, QD or BID~Escalation stage: 7 increased dose cohorts from low dose to MTD (from 40mg QD to 420mg QD)
Study: NCT04229095
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose administration of placebo given on an inpatient clinical research unit
Study: NCT05322941
Drug: AEF0117
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEF0117 (1.0, 0.3, and 0.1 mg) capsules
Study: NCT05322941
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil capsule manufactured to mimic AEF0117 capsule
Study: NCT06683300
Drug: DAPT for 3 months after vertebral artery stenting
Approvals — FDA: no, EMA: no, PMDA: no
Description: After implantation of a drug-eluting stent in the vertebral artery, dual antiplatelet therapy (DAPT) were administered for 3 months. The types of antiplatelet medications are not limited, with the standard regimen consisting of aspirin 100 mg once daily combined with either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily. Additional antiplatelet agents such as indobufen may also be considered acceptable.
Study: NCT04713631
Drug: Placebo A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate looking placebo
Study: NCT04713631
Drug: Placebo C
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin looking placebo
Study: NCT05207514
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide
Study: NCT05207514
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.
Study: NCT06332079
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT04437290
Drug: investigational radiotracer [18F]MK6240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain PET scan
Study: NCT06143241
Drug: Antiepileptic medication
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: They will continue their antiepileptic medication prescribed by their doctor.
Study: NCT05941130
Drug: Combination of corticosteroid (methylprednisolone - Medrol, 16mg Pfizer Laboratories) therapy and non-steroidal anti-inflammatory (Ibuprofen 600mg Mylan) therapy
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative steroid anti-inflammatory
Study: NCT05941130
Drug: Non-steroidal anti-inflammatory therapy (Ibuprofen 600mg Mylan)
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facial swelling assessment with a tridimensional method, pain and patient's quality of life will be evaluated after impacted third molar surgery, when NSAID are prescribed either alone (group A) or in combination with a corticosteroid (group B).Patients will be randomized before surgery into two groups regarding postoperative anti-inflammatory prescription.~Half will receive postoperative non-steroid anti-inflammatory
Study: NCT05800938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets were given twice daily for 4 weeks
Study: NCT05966272
Drug: HRS9531 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT05966272
Drug: HRS9531 injection Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT06383897
Drug: HS-10398 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14
Study: NCT05354778
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Corticosteroid
Study: NCT05389930
Drug: Alcohol placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage contains only juice and a negligible trace of alcohol for masking
Study: NCT03674320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Injection (saline) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
Study: NCT05361655
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor therapy
Study: NCT06482190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo across Part 1 and Part 2 of the study.
Study: NCT05269446
Drug: TSPO injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one dose of the non-therapeutic administration of the radioactive TSPO tracer 18F-PBR06 before a whole-body scan by uExplorer
Study: NCT05138770
Drug: VC005 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 Tablets 1、5、10、25、50、100mg single dose
Study: NCT05138770
Drug: VC005 Tablets Placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 Tablets Placebo 1、5、10、25、50、100mg single dose
Study: NCT05138770
Drug: VC005 Tablets food effects group
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC005 Tablets qd per period, for two periods
Study: NCT05131373
Drug: ORG101 - Experimental 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. acnes vaccine Injection, 25 mcg, 75 mcg, 225 mcg, 4 single i.m. injections given in monthly intervals
Study: NCT05131373
Drug: ORG101PL - Placebo 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection, sterile aqueous solution of aluminium hydroxide, 4 single i.m. injections given in monthly intervals
Study: NCT05091541
Drug: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT120 is an autologous CD19/22 targeted CAR-T cells injection. The dosage form is a cryopreserved injection solution. The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
Study: NCT06221241
Drug: JMKX000623
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets for oral administration.
Study: NCT06221241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched to JMKX000623 and Pregabalin
Study: NCT05101746
Drug: Nitric Oxide (NO) 20 part per million (ppm)
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide will be mixed into the gas flow of the cardiopulmonary bypass (CPB) oxygenator, which will be kept at 1-3 L/min to allow for the desired NO delivery rate. NO levels will be maintained at 20ppm using a NO delivery system (INOmax, Mallinckrodt).
Study: NCT03991299
Drug: Botox 200 UNT Injection
Normalized name: Botox 200 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox will be injected into duodenums of subjects by endoscopy.
Study: NCT04666701
Drug: Escócia association
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escócia association tablet
Study: NCT05872555
Drug: Psychiatric Drugs
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving any Antipsychotic, Benzodiazepine, antidepressant, mood stabilizer
Study: NCT06097923
Drug: Active fluid management with BIA monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants in active fluid management with BIA monitoring arm received fluid supplementation targeting specific range of ECW ratio by BIA (0.390-0.406). If a patient with dehydrated status indicated by the ECW ratio was less than 0.390, a bolus infusion was performed using 250ml of crystalloid fluid (PlasmaLyte). If a patient with overhydrated status indicated by the ECW ratio was more than 0.406, 10mg of furosemide was administered. Changes in the ECW ratio were measured at one hour after initial intervention for fluid adjustment, and these processes continued until the ECW ratio was within the normal range (0.390-0.406).
Study: NCT06097923
Drug: Conventional fluid management without BIA monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants in conventional fluid management without BIA monitoring arm underwent conventional fluid management without specific targets of ECW ratio by BIA.
Study: NCT04762979
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase Inhibitor, administered per standard of care
Study: NCT05797922
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 0.3mg
Study: NCT04691843
Drug: Iron Sulfate
Normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early, high dose, iron supplementation
Study: NCT04679350
Drug: hzVSF-v13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
Study: NCT06004921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT06486558
Drug: HU6 450 mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: new 450 mg tablet test formulation
Study: NCT06486558
Drug: HU6 150 mg Capsules x 3 (Total dose = 450 mg)
Normalized name: Gas-X Total Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg capsule reference formulation (3 x 150 mg).
Study: NCT06684054
Drug: docetaxel, anthracycline, cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Participants were required to receive 6 cycles of TEC/TAC neoadjuvant chemotherapy, and radical mastectomy was required after chemotherapy.~2. 5ml peripheral venous blood was collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.~3. Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.
Study: NCT05540912
Drug: D064+D701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference
Study: NCT05540912
Drug: CKD-828 Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test 2
Study: NCT06244550
Drug: Ganwei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT06244550
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsules
Study: NCT06579274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous injection can be administered quickly and directly into a vein or through an intravenous infusion set.
Study: NCT06389305
Drug: CIK cell
Normalized name: Testone CIK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: autologous or allogeneic cytokine-induced killer (CIK) cells
Study: NCT05654870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching valbenazine
Study: NCT06684158
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LV：200 mg/m2 iv gtt d1，every 2 weeks (Q2W)
Study: NCT04545151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The matching placebo will be filled into HDPE Twist-Off bottles, in the same way as the verum. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily
Study: NCT06578286
Drug: ARX788
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARX788，1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle
Study: NCT06148636
Drug: [212Pb] VMT-α-NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 2 infusions with \[212Pb\] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage.
Study: NCT05445557
Drug: RZL-012
Approvals — FDA: no, EMA: no, PMDA: no
Description: small synthetic molecule for submental fat reduction
Study: NCT05445557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06630364
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction: Sevoflurane in N2O/O2 Analgesia: Propofol (1-1.5 mg/kg), Fentanyl (1 µg/kg) Maintenance: Sevoflurane
Study: NCT05527808
Drug: cis-platemum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-75mg/m2 ,intravenous injection ,Q3W 2-4 cycles
Study: NCT05423496
Drug: steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: optimization of steroids
Study: NCT06490536
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is used as part of the chemotherapy regimens for patients with ctDNA+ and ctDNA- results in the SAGITTARIUS trial. It is administered in the following ways:~CAPOX Regimen: Capecitabine 1000 mg/m² is taken orally twice daily on days 1-14 of each 21-day cycle, in combination with oxaliplatin 130 mg/m² given intravenously on day 1.~Capecitabine Monotherapy for High-Risk ctDNA- Patients: Capecitabine 1250 mg/m² is taken orally twice daily on days 1-14 of each 21-day cycle for patients identified as high-risk but with negative ctDNA results.~The dosage of capecitabine is standardized, while the duration of treatment varies based on patient response and monitoring results, typically up to 6 months.
Study: NCT06490536
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil is used as part of the FOLFOX chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following way:~FOLFOX Regimen: Fluorouracil 400 mg/m² is given as an intravenous (IV) bolus on day 1, followed by 2400 mg/m² as a continuous IV infusion over 46 hours, in combination with folinic acid (leucovorin) 400 mg/m² IV on day 1 and oxaliplatin 85 mg/m² IV on day 1. This regimen is repeated every 14 days.~The dosage of fluorouracil is standardized, while the duration of treatment is typically up to 6 months, adjusted based on patient response and liquid biopsy results.
Study: NCT04778813
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group. Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided. These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups. The treatment to be administered will not be known until after the randomization process. The drugs will be administered based on weight according to the instructions from the drug manufacturer. AL will be administered with fatty food or milk according to the manufacturer's recommendations. All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.
Study: NCT06020300
Drug: Oral Pyridoxine 10 mg
Normalized name: pyridoxine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine look alike placebo
Study: NCT06487000
Drug: Placebo EC-18
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, QD
Study: NCT06530576
Drug: Thalidomide and methotrexate
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide at a dose of 50-100 mg/QN, Methotrexate 10 mg/m2 orally once a week.
Study: NCT06435481
Drug: 3D printed chewable formulation of hydrocortisone
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of a novel hydrocortisone formulation provided as chewable tablets. Each tablet, manufactured with a volume dosing device (3D printer), contains a precise dosage of hydrocortisone.
Study: NCT06435481
Drug: Oral suspension of hydrocortisone
Normalized name: hydrocortisone Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a standard hydrocortisone oral suspension. The solution, based on simple syrup, contains 1mg of hydrocortisone per milliliter.
Study: NCT05461755
Drug: Topical Tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of striae with topical tretinoin alone
Study: NCT06577701
Drug: non traditional Chinese medicine (non-TCM)
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure was defined as taking the medication continuously for more than 3 months per year, or taking the medication intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group was divided into an exposed group (TCM protocols cohort) and a non-exposed group (non-TCM protocols cohort).
Study: NCT04836962
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2cc of normal saline is administered to patient instead of dexamethasone.
Study: NCT05969457
Drug: Naropeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia with injection of Ropivacaine (20mL of ropivacaine 7.5 mg/mL, i.e. 150mg)
Study: NCT06461299
Drug: Seysara Oral Product
Normalized name: Seysara Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with a clinical diagnosis of POD will be given sarecycline for four weeks. Dosing of sarecycline will be weight based, either 60mg, 100mg, or 150mg PO qday. Each subject will have at least three visits, including a screening/baseline visit, a two-week follow-up, and a four-week follow-up. The initial diagnosis will be made by a board-certified dermatologist or a dermatology-certified nurse practitioner. The Perioral Dermatitis Severity Index, PODSI, (Appendix I) will be used to grade the severity of periorificial dermatitis throughout the three visits. This published scoring method ranges from 0 to 9. To be included in the study, patients must need to have a PODSI score of moderate (PODSI = 3.0-5.5) or severe (PODSI = 6.0-9.0) at baseline. The primary endpoint is the percentage of patients that receive a PODSI score ranging from 0 (none) to 2.5 (mild) at week four. The secondary endpoint is the patient reported an adverse event at week four.
Study: NCT06433531
Drug: TQH2929 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
Study: NCT06141330
Drug: Azithromycin 250 milligram Oral Capsule
Normalized name: azithromycin 250 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anti Biotic
Study: NCT05867654
Drug: oral clindamycin 300mg q6hrs
Normalized name: clindamycin 300 MG
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral antibiotic used based on indication
Study: NCT05953688
Drug: ESK-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06576388
Drug: EXG001-307 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Research process includes filter (subjects signed informed consent for screening period before the pretreatment to the hormone, the longest 28 days), treatment period (the subjects accept including single hormone pretreatment, the study drug infusion) hospitalization and observation and follow-up treatment period (subjects to the participants to 18 months, lost to follow-up, active exit research subjects, or death). Subjects qualified in the screening period entered the treatment period and received EXG001-307, and entered the follow-up period after hospitalization. At the end of the study visit (subject at 18 months of age), eligible subjects will be asked to transfer to the long-term follow-up study.
Study: NCT05018923
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1g bid
Study: NCT05018923
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5g qid
Study: NCT05004909
Drug: 0.05% Tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
Study: NCT05542147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet per day
Study: NCT05650645
Drug: Placebo-Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections will be preservative free normal saline. Injections will be administered similar to the drug injections.
Study: NCT05417880
Drug: Oral Hypoglycemic Agents,Oral
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with routine current oral hypoglycemic agents for 3-6 months
Study: NCT05417880
Drug: Voreta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg oral tablets Once Daily for 3-6 months
Study: NCT00035074
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06666673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as control
Study: NCT05765279
Drug: Placebo Comparator 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray 5 times daily for 3 consecutive days
Study: NCT05765279
Drug: Placebo Comparator 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray 8 times daily for 3 consecutive days
Study: NCT06562894
Drug: SYHX1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily (QD)